Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
completion around

Description

Summary

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Official Title

A Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma

Keywords

Hepatocellular Cancer, Liver Neoplasms, Hepatocellular Carcinoma

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Male or female patients, age ≥18 years
  2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC cholangiocarcinoma may be included; patients who are candidates for surgical and non-surgical treatment, as well as those being followed without specific HCC therapy may be included)

You CAN'T join if...

  1. Inability to provide written informed consent

Locations

  • University of California-Davis in progress, not accepting new patients
    Sacramento California 95817 United States
  • University of California in progress, not accepting new patients
    San Francisco California 94158 United States
  • University of Pennsylvania accepting new patients
    Philadelphia Pennsylvania 19104 United States
  • Universitätsklinikum Düsseldorf accepting new patients
    Düsseldorf Germany
  • Universitätsklinikum Frankfurt terminated
    Frankfurt Germany
  • Medizinische Hochschule Hannover terminated
    Hannover Germany
  • Universitätsklinikum Leipzig terminated
    Leipzig Germany
  • Universitätsklinikum Magdeburg terminated
    Magdeburg Germany
  • Universitätsmedizin Mainz terminated
    Mainz Germany

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Target PharmaSolutions, Inc.
ID
NCT02954094
Study Type
Observational [Patient Registry]
Participants
Expecting 10000 study participants
Last Updated